ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that the first patient was enrolled in the EAST (Early comprehensive Atrial fibrillation Stroke prevention Trial) clinical trial. The investigator-initiated study seeks to determine whether an early, comprehensive, standardized intervention program can help prevent adverse cardiovascular outcomes associated with prolonged Atrial Fibrillation (AF), including stroke and death. More specifically, the EAST study will evaluate whether an early and comprehensive rhythm control treatment of patients with early onset AF produces better patient outcomes than usual care alone.
